Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04129320
Recruitment Status : Withdrawn (Change in study design)
First Posted : October 16, 2019
Last Update Posted : October 14, 2020
Sponsor:
Information provided by (Responsible Party):
MacroGenics

No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : October 2020
Estimated Study Completion Date : October 2022